 Asian Scientist Magazine | Bristol-Myers Squibb Booked a New High TradersHuddle.com The Company offers products and experimental therapies to address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. Bristol-Myers Squibb is currently trading 0.71% versus ... Bristol-Myers Squibb: Exec Insider and Fund Stock Sales in Q3 Bristol-Myers Squibb: 52-Week High Recently Eclipsed (BMY) |
